SIX1 and EYA1, two important RDGN members, exert favorable effects on tumor initiation and progression4, 5, and high expression of SIX1 and EYA1 is an adverse factor for clinical outcomes for breast cancer patients6–8. Here, SIX1 is linked to neoplasm.